Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme gets FDA notice of additional re-inspection of US Allston plant

This article was originally published in Scrip

Executive Summary

The US FDA has informed Genzyme that it will re-inspect the company's Allston, Massachusetts manufacturing plant as a follow-up to a re-inspection that took place in May. News of yet another inspection came as a surprise to both the company and investors, as they thought all outstanding issues from the February 27th, 2009 FDA warning letter had all been addressed.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts